Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 23-31

  Zernig, Gerald ^a   Burke, Timothy ^a   Lewis, John W ^c   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREMAZOCINE; CLOCINNAMOX; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; METHOCLOCINNAMOX; MU OPIATE RECEPTOR; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMPETITION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TAIL FLICK TEST;

ANIMALS; BEHAVIOR, ANIMAL; BENZOMORPHANS; CINNAMATES; CYCLOHEXIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; MALE; MICE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU;

EID: 0030440958     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ACETO, M. D., BOWMAN, E. R., MAY, E. L., HARRIS, L. S., WOODS, J. H., SMITH, C. B., MEDZIHRADSKY, F. AND JACOBSON, A. E.: Very long-acting narcotic antagonists: The 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim. Forsch./Drug Res. 39: 570-575, 1989.
2. BLACK, J. W. AND LEFF, P.: Operational models of pharmacological agonism. Proc. R. Soc. Lond. B 220: 141-162, 1983.
3. BRADFORD, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
4. BURKE, T. F., WOODS, J. H., LEWIS, J. W. AND MEDZIHRADSKY, F.: Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J. Pharmacol. Exp. Ther. 271: 715-721, 1994.
5. COMER, S. D., BURKE, T. F., LEWIS, J. W. AND WOODS, J. H.: Clocinnamox: A novel, systemically active irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 262: 1051-1056, 1992.
6. FISCHEL, S. V. AND MEDZIHRADSKY, F.: Scatchard analysis of opiate receptor binding. Mol. Pharmacol. 20: 269-279, 1981.
7. FLEMING, W. W., WESTFALL, D. P., DE LA LANDE, I. S. AND JELLETT, L. B.: Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J. Pharmacol. Exp. Ther. 181: 339-345, 1972.
8. FURCHGOTT, R. F.: The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3: 21-56, 1966.
9. GRAZIADEI, I., ZERNIG, G., GRASSEGGER, A., BOER, R., SCHUDT, C. AND GLOSSMANN, H.: Hydrophobic calcium channel ligands: Methodical problems and their solution. Am. J. Cardiol. 64: 43I-50I, 1989.
10. 3 aromatic ring in cyclic delta opioid receptor-selective dermorphin/deltorphin tetrapeptide analogues: Electronic and lipophilic requirements for receptor affinity. J. Med. Chem. 35: 1535-1541, 1992.
11. JANSSEN, P. A. J., NIEMEGEERS, J. E. AND DONY, J. G. H.: The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneim. Forsch./Drug Res. 13: 502-507, 1963.
12. 3H]naloxonazine to rat brain membranes. Mol. Pharmacol. 26: 477-483, 1984.
13. KENAKIN, T. P.: Pharmacologic Analysis of Drug-Receptor Interaction, 2nd ed., Raven Press, New York, 1993.
14. LEWIS, J. W., SMITH, C., MCCARTHY, P., WALTER, D., KOBYLECKI, R., MYERS, M., HAYNES, A., LEWIS, C. AND WALTHAM, K.: New 14-aminomorphinones and codeinones. NIDA Res. Monogr. 90: 136-143, 1988.
15. LINDEN, J.: Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%. J. Cycl. Nucl. Res. 8: 163-172, 1982.
16. 3H]beta-funaltrexamine binding to mu opioid receptor. Mol. Pharmacol. 37:243-250, 1990.
17. MANSOUR, A. AND WATSON, S. J.: Anatomical distribution of opioid receptors in mammalians: An overview, In: Handbook of Experimental Pharmacology: Opioids I, ed. by A. Herz, pp. 79-105, Springer, New York, 1993.
18. PASTERNAK, G. W.: Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16: 1-18, 1993.
19. PORTOGHESE, P. S., LARSON, D. L., SAYRE, L. M., FRIES, D. S. AND TAKEMORI, A. E.: A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J. Med. Chem. 23: 233-234, 1980.
20. QUINTON, E. E. AND KRAMARCY, N. R.: Memory impairment correlates closely with cycloheximide dose and degree of inhibition of protein synthesis. Brain Res. 131: 184-190, 1977.
21. REMMERS, A. E. AND MEDZIHRADSKY, F: Resolution of biphasic binding of the opioid antagonist naltrexone in brain membranes. J. Neurochem. 57: 1265-1269, 1991.
22. SPERK, G., STEWART, R. M., CAMPBELL, A. AND BALDESSARINI, R. J.: Inhibition of 5,7-dihydrotryptamine-induced supersensitivity to 5-hydroxytryptophan in mice by treatment with cycloheximide. Brain Res. 159: 183-194, 1978.
23. TAKEMORI, A. E., LARSON, D. L. AND PORTOGHESE, P. S.: The irreversible narcotic antagonistic and reversible agonistic properties of the fumarate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 70: 445-451, 1981.
24. R: A System for Doing Mathematics by Computer, Addison-Wesley Publishing Company, Reading, MA, 1991.
25. WOODS, J. H., LEWIS, J. W., WINGER, G., BUTELMAN, E., BROADBEAR, J. AND ZERNIG, G.: Methoclocinnamox: A mu-partial agonist with pharmacotherapeutic potential for heroin abuse. NIDA Res. Monogr. 147: 195-219, 1995.
26. ZERNIG, G., BROADBEAR, J. H., LEWIS, J. W., BRINE, G. A. AND WOODS, J. H.: Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox. Exp. Clin. Psychopharmacol. 3: 323-329, 1995a.
27. ZERNIG, G., BUTELMAN, E. R., LEWIS, J. W., WALKER, E. A. AND WOODS, J. H.: In vivo determination of mu opiod receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 269: 57-65, 1994.
28. ZERNIG, G., ISSAEVITCH, T., BROADBEAR, J., BURKE, T., LEWIS, J. W., BRINE, G. A. AND WOODS, J. H.: Receptor reserve and affinity of mu opioid agonists in mouse antinociception: Correlation with receptor binding. Life Sci. 57:2113-2125, 1995b.
29. ZERNIG, G., ISSAEVITCH, T. AND WOODS, J. H.: Calculation of agonist efficacy, apparent affinity and receptor population changes: Comparison of different analytical approaches. J. Pharmacol. Toxicol. Methods, 35:223-237, 1996a.
30. 3H]-clocinnamox binding in mouse brain membranes. Analgesia 1: 874-877, 1995c.
31. ZERNIG, G., WINGER, G. D., ISSAEVITCH, T., LEWIS, J. W. AND WOODS, J. H.: Clocinnamox effects on intravenous self-administration of mu opioid agonists and cocaine by rhesus monkeys: Agonist efficacy and affinity estimates. NIDA Res. Monogr., 162:341, 1996b.